Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer. - Wikidata - awgldk - TriplyDB

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

http://www.wikidata.org/entity/Q33409522

about

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

P2860

Q35798931-50E53B96-CD5C-4872-8EF5-938E822DDE1F Q37420213-2DE91BD7-4A10-434A-9DB4-2369DFDB898E

P2860

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

http://www.wikidata.org/entity/Q33409522

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

@ast

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

@en

type

label

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

@ast

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

@en

prefLabel

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

@ast

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

@en

P1433

Q33409522-9AFA4F63-696E-425A-AF7C-A109AAD75440

P1476

Q33409522-3D0A07EA-78FC-423A-9332-88A7FBFF7ABF

P2093

Q33409522-1F9137CD-3B41-4016-B94C-2EE3583BE42E

Q33409522-2407B451-2528-49EE-915C-D19C51CE3A45

Q33409522-529D6F85-DA75-4305-AF01-743CEF0E3D29

Q33409522-64F55AC9-9A0F-4CDA-9F35-73714479E2E6

Q33409522-A6053F11-91DD-400A-B9FF-C51962019BBD

Q33409522-BEAC53B1-4BA4-4557-A5B9-040691959151

Q33409522-D5FBD276-03C4-4DAB-B782-D836E9EDFC6D

Q33409522-DE776F40-3BF3-40D9-8698-56BC20D11302

P2860

Q33409522-212EE3C2-FC56-40C8-9423-79DEFAF89F2E

Q33409522-3087C4F2-F27A-44EA-AFEF-49FDC6041F7A

Q33409522-3148CCB5-9A56-428F-A101-51D3C087AFFF

Q33409522-49011082-B5D2-477B-B73A-4EE2D956D093

Q33409522-517330E1-FE7D-45A5-AA4A-687F0419C0EE

Q33409522-57482083-2B29-4606-B7E4-CB9954B93A76

Q33409522-6D7AD863-4823-44B8-AC5E-2D2C937A30DD

Q33409522-869C4BAE-C022-443D-BB08-75A7CBE3F4E8

Q33409522-97D514A8-AC29-4656-8F45-AD6F4D925422

Q33409522-9ED1D9B1-51CF-4102-AD99-30784BDA8E8A

P2888

Q33409522-FFC58767-785B-4A35-8375-A327865ACB33

P304

Q33409522-A43B66F5-BBD9-4225-B54A-99234F6DC59F

P31

Q33409522-00129641-9166-49BA-BC73-273C58D5CD0D

P356

Q33409522-923FDACF-4D2B-40BD-A669-A2FA51CD6021

P433

Q33409522-9DCEC53A-572E-42FC-99EA-45EA2A86209C

P478

Q33409522-CECEC759-9EBF-4D22-9879-E4E6E5ADA7E7

P577

Q33409522-748A41E4-B76F-4924-A81C-24060CF58D6D

P6179

Q33409522-E8F2EDBE-EB75-4D1F-9DFB-7F8408E6EBCA

P698

Q33409522-B9E73867-A438-4501-9FCA-1B9395DCE7BB

P921

Q33409522-41D27B82-0F95-4D65-AFBA-7F3EED8BB4ED

P356

S00280-013-2241-7

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.

@en

P2093

Byoung-Gie Kim

http://www.w3.org/2001/XMLSchema#string

Chel Hun Choi

http://www.w3.org/2001/XMLSchema#string

Duk Soo Bae

http://www.w3.org/2001/XMLSchema#string

Jeong-Won Lee

http://www.w3.org/2001/XMLSchema#string

Min Kyu Kim

http://www.w3.org/2001/XMLSchema#string

Tae-Joong Kim

http://www.w3.org/2001/XMLSchema#string

Taejong Song

http://www.w3.org/2001/XMLSchema#string

Yoo-Young Lee

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.

Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.

Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study.

Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer.

Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.

A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.

Current management of epithelial ovarian carcinoma: a review.

Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.

Use of CA-125 to assess response to new agents in ovarian cancer trials.

P2888

s00280-013-2241-7

P304

653-660

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-013-2241-7

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017104095

http://www.w3.org/2001/XMLSchema#string

P698

23912693

http://www.w3.org/2001/XMLSchema#string

P921